MicuRx Pharmaceuticals Obtains $2,500,000 Series B Financing Round

  • Feed Type
  • Date
    8/22/2013
  • Company Name
    MicuRx Pharmaceuticals
  • Mailing Address
    3916 Trust Way Hayward, CA 94545
  • Company Description
    MicuRx is discovering and developing next-generation antibacterial andantifungal products. By making specific modifications to validatedantibiotics, MicuRx intends to improve overall pharmacological propertiesof antimicrobial drugs in order to overcome antibiotic resistance, increasethe antibacterial spectrum, improve the dosing regimen, or reduce adverseside effects.
  • Website
    http://www.micurx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $2,500,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the Series B financing will be used to fund the U.S. development of MRX-I, a novel oral oxazolidinone antibiotic targeting infections due to multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
  • M&A Terms
  • Venture Investor
    BVCF
  • Venture Investor
    BVCF
  • Venture Investor
    Morningside Group
  • Venture Investor
    Devon Park Bioventures